What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “all patients will receive one injection of \[18F\]XTR006, a PET radiopharmaceutical selective for NFTs. For the injection, subjects will receive a target dose of 4-6 mCi IV as a bolus injection. \[18F\]XTR006 injection will be followed by a 10 ml saline flush.”In the company’s words, NCT07115238 on ClinicalTrials.gov
- Tested for
- Alzheimer Disease, Neurofibrillary Tangle
- Main trialPhase 3
- “The goal of this clinical trial is to evaluate the efficacy and safety of XTR006 injection PET visual reading in detecting brain neurofibrillary tangles (NFTs) in elderly subjects with Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD), and cognitively normal individuals. The main question it aims to answer is: • What is the sensitivity and specificity of XTR006 PET visual reading results compared to the truth standard across MCI, AD, and cognitively normal subjects? Participants will: * Receive XTR006 injection * Undergo PET/CT scanning”In the company’s words, NCT07115238 on ClinicalTrials.gov
- Other names
- Florquinitau
Other drugs for Alzheimer Disease
- Xanomeline/Trospium ChlorideBristol Myers Squibb · Phase 3
- -APN-1607JYAMS PET Research & Development Limited · Phase 3
- LecanemabEisai · Biogen · Phase 3
- DMB-IBigespas LTD · Phase 3
- TrontinemabRoche · Phase 3
- Buntanetap/posiphenAnnovis Bio Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Dec 2025 | Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD | |
| Phase 2Authorised | not given | Longitudinal multicenter head-to-head harmonization of tau PET tracers (HEAD Study) | |
| Phase 3/4Authorised | not given | Cognitive brain circuits and the spread of tau in vivo in humans. | |
| Phase 2/3Authorised | not given | A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer’s Disease (DIAD) | |
| Phase 2/3Authorised | not given | Tau and Amyloid PET imaging in normal aging, early Alzheimer's disease and related syndroms. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026